ClinicalTrials.gov record
Terminated Phase 1Phase 2 Interventional

Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

ClinicalTrials.gov ID: NCT03709082

Public ClinicalTrials.gov record NCT03709082. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I/II Study of Palbociclib, Letrozole and T-DM1 in Trastuzumab Refractory Estrogen Receptor Positive (ER+) and HER2 Positive Metastatic Breast Cancer

Study identification

NCT ID
NCT03709082
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
University of Kansas Medical Center
Other
Enrollment
3 participants

Conditions and interventions

Interventions

  • Letrozole 2.5mg Drug
  • Palbociclib Drug
  • Palbociclib 100mg Drug
  • Palbociclib 125mg Drug
  • Palbociclib 75mg Drug
  • T-DM1 Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 14, 2018
Primary completion
Mar 11, 2020
Completion
Feb 2, 2021
Last update posted
Mar 4, 2024

2018 – 2021

United States locations

U.S. sites
5
U.S. states
2
U.S. cities
4
Facility City State ZIP Site status
The University of Kansas Cancer Center, West Clinic Kansas City Kansas 66112
The University of Kansas Cancer Center, Westwood Campus Kansas City Kansas 66205
The University of Kansas Cancer Center, Overland Park Clinic Overland Park Kansas 66210
The University of Kansas Cancer Center, North Clinic Kansas City Missouri 64154
The University of Kansas Cancer Center, Lee's Summit Clinic Lee's Summit Missouri 64064

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03709082, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 4, 2024 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03709082 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →